ONS-76 Xenograft Model Service for Medulloblastoma

The ONS-76 xenograft model represents one of the most reliable and well-characterized preclinical platforms for medulloblastoma research, offering robust tumorigenic potential and molecular fidelity to pediatric brain tumor biology. Alfa Cytology delivers comprehensive ONS-76 xenograft model services tailored to your drug discovery and development pipeline, combining rigorous quality control with flexible study designs to accelerate your preclinical research objectives.

Overview of ONS-76 Xenograft Model for Medulloblastoma

Medulloblastoma is the most common malignant brain tumor in pediatric populations, classified into four major molecular subgroups: WNT, SHH, Group 3, and Group 4. The ONS-76 cell line, established in 1987 from cerebellar tumor tissue of a 2-year-old Japanese female patient, has emerged as a critical model system for preclinical medulloblastoma research. Molecular profiling classifies ONS-76 within the SHH subgroup with wild-type TP53 status, and the cells exhibit epithelial-like morphology with colony-forming growth patterns. ONS-76 demonstrates the highest proliferative potential among commonly used medulloblastoma cell lines, with a cell doubling time of approximately 22 hours, and possesses confirmed in vivo tumorigenic potential in immunodeficient mouse models.

The ONS-76 cell line expresses neural progenitor markers including SOX2 and Nestin alongside neuronal differentiation markers such as neuron-specific enolase (NSE) and neurofilament proteins. Notably, ONS-76 exhibits elevated VE-cadherin (CDH5) expression and CD133-positive subpopulations, suggesting stem-like characteristics relevant to tumor initiation and therapeutic resistance studies. The cell line also demonstrates inducible MHC-II expression following interferon-gamma stimulation, making it valuable for immunotherapy and tumor microenvironment investigations. These combined features render the ONS-76 xenograft model particularly suitable for evaluating targeted therapeutics, radiation response, and novel treatment strategies in pediatric neuro-oncology.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting SHH subgroup medulloblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving medulloblastoma progression through SHH signaling, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for stem cell marker and immunotherapy studies.

Figure 1. Cadherins gene expression levels in the medulloblastoma cell lines. (Bonfim-Silva, R, et al., 2019)

Cell Line Information: ONS-76

The ONS-76 cell line was originally established from a primary cerebellar medulloblastoma specimen and has been extensively characterized across multiple molecular and functional dimensions. Its classification within the SHH subgroup and highest proliferative potential among medulloblastoma cell lines makes it unique and essential for preclinical research targeting this aggressive pediatric brain tumor subtype.

Our Services

Alfa Cytology leverages the well-established ONS-76 cell line to deliver high-quality xenograft models with reproducible tumor growth kinetics and consistent molecular profiles. Our preclinical platform integrates rigorous cell line authentication, optimized implantation protocols, and comprehensive endpoint analysis to ensure reliable data generation for your medulloblastoma therapeutic development programs. Whether you require standard subcutaneous models or advanced orthotopic cerebellar implantations, our scientific team provides end-to-end support from study design through data delivery.

Workflow of ONS-76 Xenograft Model Construction

The construction of ONS-76 xenograft models follows a standardized yet adaptable workflow designed to ensure tumor engraftment consistency, animal welfare compliance, and data integrity. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Authentication and Quality Control: ONS-76 cells are authenticated via STR profiling and confirmed for mycoplasma negativity prior to expansion. Cells are maintained in RPMI-1640 or MEM supplemented with 10% FBS under standard culture conditions until reaching optimal confluence for harvest.
2. Cell Harvest and Preparation: Cells are harvested at logarithmic growth phase using trypsin-EDTA digestion, washed with PBS, and resuspended in serum-free medium or Matrigel mixture at appropriate concentrations (typically 1x10^6 to 5x10^6 cells per injection site).
3. Recipient Animal Selection and Preparation: Immunodeficient nude mice (nu/nu) or NOD-SCID mice are selected based on study requirements. Animals are acclimatized for 5-7 days, with health status verified prior to tumor cell inoculation.
4. Tumor Cell Implantation: ONS-76 cells are implanted via subcutaneous flank injection or orthotopic cerebellar injection depending on study design. For orthotopic models, stereotactic injection into the cerebellar region is performed under anesthesia.
5. Post-Implantation Monitoring: Animals are monitored daily for general health, body weight, and neurological signs. Tumor dimensions are measured using calipers every 2-3 days beginning at day 7 post-injection, with tumor volume calculated using the formula: (length x width^2)/2.
6. Treatment Administration: Test compounds, radiation, or combination therapies are administered according to predefined dosing schedules once tumors reach target volumes (typically 100-200 mm^3). Treatment responses are monitored through serial tumor measurements.
7. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathology, immunohistochemistry, molecular analysis, or pharmacokinetic studies. Blood and organ samples are collected for toxicity assessment as required.

Figure 2: Schematic workflow illustrating the derivation and construction of the ONS-76 Xenograft Model at Alfa Cytology.

Case Study-ONS-76 Xenograft Model Development

Alfa Cytology has successfully established and validated the ONS-76 xenograft model as part of our expanding pediatric brain tumor platform. In our internal validation studies, ONS-76 cells demonstrated consistent tumor engraftment rates with predictable growth kinetics across multiple experimental cohorts. Tumor-bearing animals exhibited measurable tumor volumes within 7-15 days post-implantation, with progressive tumor growth observed throughout the 60-day monitoring period. Comprehensive histopathological and molecular characterization confirmed maintenance of medulloblastoma phenotypic features in the xenograft setting, including expression of relevant neural and stem cell markers. Detailed quantitative data including tumor growth curves, survival metrics, and pharmacological response profiles are available upon formal inquiry and protected under client confidentiality agreements.

Why Choose Alfa Cytology?

Alfa Cytology distinguishes itself as a specialized preclinical CRO dedicated to advancing oncology research through rigorous model development and client-centered scientific collaboration. Our ONS-76 xenograft model service is built upon technical excellence, operational transparency, and a commitment to delivering actionable preclinical data.

• Verified Cell Line Integrity: Extensive experience in pediatric brain tumor model development with validated ONS-76 xenograft protocols.
• High Take Rates and Consistency: Comprehensive cell line authentication and quality assurance procedures ensuring model fidelity and reproducibility.
• Comprehensive Analytical Support: Flexible study designs accommodating subcutaneous, orthotopic, and combination therapy evaluation paradigms.
• Tailored Study Designs: Integrated endpoint analysis capabilities spanning histopathology, immunohistochemistry, molecular profiling, and biomarker assessment.
• Standardized Protocols: Dedicated project management with transparent communication and milestone-based reporting throughout the study lifecycle.
• Dedicated Project Management: Competitive turnaround times without compromising scientific rigor or animal welfare standards.

Contact Us

Ready to advance your medulloblastoma therapeutic program with a validated ONS-76 xenograft model? Contact us today to discuss your specific research requirements, obtain a detailed project proposal, and explore how Alfa Cytology can support your preclinical development objectives. Please reach out to us today via our inquiry form or email to learn more about our ONS-76 Xenograft Model services.

For research use only. Not intended for any clinical use.